Related Experiment Video
Updated: May 5, 2026
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR
Pierre Tennstedt1, Charlotte Bölch2, Gundula Strobel2
1Martini-Clinic, Section for Translational Prostate Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract:
Tumor protein D52 (TPD52) is located at chromosome 8q21, a region that is frequently gained or amplified in multiple human cancer types. TPD52 has been suggested as a potential target for new anticancer therapies. In order to analyze TPD52 expression in the most prevalent human cancer types, we employed quantitative PCR to measure TPD52 mRNA levels in formalin-fixed tissue samples from more than 900 cancer tissues obtained from 29 different human cancer types. TPD52 was expressed at varying levels in all tested normal tissues, including skin, lymph node, lung, oral mucosa, breast, endometrium, ovary, vulva, myometrium, liver, pancreas, stomach, kidney, prostate, testis, urinary bladder, thyroid gland, brain, muscle and fat tissue. TPD52 was upregulated in 18/29 (62%) tested cancer types. Strongest expression was found in non-seminoma (56-fold overexpression compared to corresponding normal tissue), seminoma (42-fold), ductal (28-fold) and lobular breast cancer (14-fold). In these tumor types, TPD52 upregulation was found in the vast majority (>80%) of tested samples. Downregulation was found in 11 (38%) tumor types, most strongly in papillary renal cell cancer (-8-fold), leiomyosarcoma (-6-fold), clear cell renal cell cancer (-5-fold), liposarcoma (-5-fold) and lung cancer (-4-fold). These results demonstrate that TPD52 is frequently and strongly upregulated in many human cancer types, which may represent candidate tumor types for potential anti-TPD52 therapies.
Insights
Tumor protein D52 (TPD52) is frequently overexpressed in many cancers, particularly breast and testicular tumors. This protein
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The Tumor Protein D52 (TPD52) gene is located on chromosome 8q21, a region often amplified in human cancers.
- TPD52 is implicated as a potential therapeutic target for novel anticancer strategies.
Purpose of the Study:
- To investigate TPD52 mRNA expression across a wide spectrum of prevalent human cancer types.
- To identify specific cancer types with significant TPD52 upregulation or downregulation.
Main Methods:
- Quantitative PCR (qPCR) was utilized to measure TPD52 mRNA levels.
- Analysis was performed on over 900 formalin-fixed tissue samples from 29 distinct human cancer types.
- TPD52 expression in tumor tissues was compared to corresponding normal tissues.
Main Results:
- TPD52 was expressed in all tested normal tissues.
- Upregulation of TPD52 was observed in 62% (18/29) of cancer types analyzed.
- The highest TPD52 overexpression was detected in non-seminoma, seminoma, ductal breast cancer, and lobular breast cancer.
- Downregulation of TPD52 was found in 38% (11/29) of cancer types, notably papillary and clear cell renal cell carcinoma, leiomyosarcoma, liposarcoma, and lung cancer.
Conclusions:
- TPD52 exhibits frequent and significant differential expression across numerous human cancers.
- The observed upregulation in specific tumor types suggests TPD52 as a promising candidate for targeted anticancer therapies.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
06:06High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024